Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI110339

Increase of lymphocytes with Fc receptors for IgE in patients with allergic rhinitis during the grass pollen season.

H L Spiegelberg and R A Simon

Find articles by Spiegelberg, H. in: PubMed | Google Scholar

Find articles by Simon, R. in: PubMed | Google Scholar

Published October 1, 1981 - More info

Published in Volume 68, Issue 4 on October 1, 1981
J Clin Invest. 1981;68(4):845–852. https://doi.org/10.1172/JCI110339.
© 1981 The American Society for Clinical Investigation
Published October 1, 1981 - Version history
View PDF
Abstract

Peripheral blood lymphocytes from 10 nonallergic donors and 7 patients suffering from seasonal allergic rhinitis and receiving desensitization therapy were analyzed by rosette assays for Fc receptors for IgE (Fc epsilon R) and IgG (Fc gamma R) before, during and after the grass pollen season. Six of seven patients had moderately elevated IgE levels (330 +/- 268 IU/ml), all had high titers of skin sensitizing antibodies to grass pollens and serum IgE antibodies as measured by radio-allergosorbent tests (RAST). Seven of the nonallergic donors had 2-30 IU/ml IgE and negative RAST, whereas three had 91-267 IU/ml IgE and two were RAST positive to the grass pollens. In March, when the patients were asymptomatic, the mean +/-SD of the Fc epsilon R+ lymphocytes did not significantly differ from the nonallergic control group: nonallergic Fc epsilon R+ 1.2 +/- 0.9% (29 +/- 20/,mm3), allergic Fc epsilon R+ 2.0 +/- 3.1% (48 +/- 52/mm3). In contrast, during the grass pollen season in May and June, when the patients developed symptoms of allergic rhinitis, they had significantly (P less than 0.01) more Fc epsilon R+ lymphocytes than the controls: nonallergic Fc epsilon R+ 1.7 +/- 1.9% (40 +/- 46/mm3), allergic Fc epsilon R+ 4.7 +/- 1.2% (134 +/- 69/mm3). In the postpollen period, August-October, most of the patients again had low numbers of Fc epsilon R+ lymphocytes: nonallergic Fc epsilon R+ 1.4 +/- 0.9% (26 +/- 13/mm3), allergic Fc epsilon R+ 2.1 +/- 1.9% (62 +/- 82/mm3). The nonallergic control donors with elevated IgE levels and positive RAST always had low numbers of Fc epsilon R+ lymphocytes. In contrast, two other nonallergic donors, who had a 2-7 IU/ml IgE and negative RAST, showed significant increases of Fc epsilon R+ lymphocytes over several weeks during the grass pollen season. No statistically significant changes in Fc gamma R+ lymphocytes occurred in both nonallergic and allergic donors. The total and specific IgE serum levels did not vary much in the nonallergic donors and patients during the period of study and any changes that did occur did not correlate with the changes in Fc epsilon R+ lymphocytes. The data demonstrate that Fc epsilon R+ peripheral blood lymphocytes increase in allergic patients during natural antigen exposure and active disease in the absence of measurable increases of total and specific serum IgE. Because two nonallergic control donors also had temporary increases of Fc epsilon R+ lymphocytes, an increase of peripheral blood Fc epsilon R+ lymphocytes may be a sensitive indicator of an ongoing IgE immune response.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 845
page 845
icon of scanned page 846
page 846
icon of scanned page 847
page 847
icon of scanned page 848
page 848
icon of scanned page 849
page 849
icon of scanned page 850
page 850
icon of scanned page 851
page 851
icon of scanned page 852
page 852
Version history
  • Version 1 (October 1, 1981): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts